Potentiation of methamphetamine neurotoxicity by intrastriatal lipopolysaccharide administration

Akaneya, 1995, Interleukin-1 beta enhances survival and interleukin-6 protects against MPP+ neurotoxicity in cultures of fetal rat dopaminergic neurons, Exp. Neurol., 136, 44, 10.1006/exnr.1995.1082 Arai, 2004, Neurotoxic effects of lipopolysaccharide on nigral dopaminergic neurons are mediated by microglial activation, interleukin-1β, and expression of caspase-11 in mice, J. Biol. Chem., 279, 51647, 10.1074/jbc.M407328200 Arimoto, 2003, Up-regulation of inducible nitric oxide synthase in the substantia nigra by lipopolysaccharide causes microglial activation and neurodegeneration, Neurobiol. Dis., 12, 35, 10.1016/S0969-9961(02)00017-7 Arimoto, 2007, Interleukin-10 protects against inflammation-mediated degeneration of dopaminergic neurons in substantia nigra, Neurobiol. Aging, 28, 894, 10.1016/j.neurobiolaging.2006.04.011 Asanuma, 2003, Methamphetamine-induced neurotoxicity in mouse brain is attenuated by ketoprofen, a non-steroidal anti-inflammatory drug, Neurosci. Lett., 352, 13, 10.1016/j.neulet.2003.08.015 Asanuma, 2004, Specific gene expression and possible involvement of inflammation in methamphetamine-induced neurotoxicity, Ann. N.Y. Acad. Sci., 1025, 69, 10.1196/annals.1316.009 Benedetti, 1980, Identification of 4-hydroxynonenal as a cytotoxic product originating from the peroxidation of liver microsomal lipids, Biochim. Biophys. Acta, 620, 281, 10.1016/0005-2760(80)90209-X Bennett, 1999, Degradation of alpha-synuclein by proteasome, J. Biol. Chem., 274, 33855, 10.1074/jbc.274.48.33855 Betarbet, 2000, Chronic systemic pesticide exposure reproduces features of Parkinson's disease, Nat. Neurosci., 3, 1301, 10.1038/81834 Bing, 1994, Locus coeruleus lesions potentiate neurotoxic effects of MPTP in dopaminergic neurons of the substantia nigra, Brain Res., 668, 261, 10.1016/0006-8993(94)90534-7 Block, 2005, Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism, Prog. Neurobiol., 76, 77, 10.1016/j.pneurobio.2005.06.004 Campbell, 1993, Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6, Proc. Natl. Acad. Sci. U.S.A., 90, 10061, 10.1073/pnas.90.21.10061 Cannon, 2009, A highly reproducible rotenone model of Parkinson's disease, Neurobiol. Dis., 34, 279, 10.1016/j.nbd.2009.01.016 Cerruti, 1995, Involvement of oxidative and L-arginine-NO pathways in the neurotoxicity of drugs of abuse in vitro, Clin. Exp. Pharmacol. Physiol., 22, 381, 10.1111/j.1440-1681.1995.tb02025.x Chalmers, 1971, Effects of L-dopa on norepinephrine metabolism in the brain, Proc. Natl. Acad. Sci. U.S.A., 68, 662, 10.1073/pnas.68.3.662 Chiang, 1994, Reactive gliosis as a consequence of interleukin-6 expression in the brain: studies in transgenic mice, Dev. Neurosci., 16, 212, 10.1159/000112109 Choi, 2009, Striatal neuroinflammation promotes Parkinsonism in rats, PLoS One, 4, e5482, 10.1371/journal.pone.0005482 Danielson, 2008, Oxidative and nitrative protein modifications in Parkinson's disease, Free Radic. Biol. Med., 44, 1789, 10.1016/j.freeradbiomed.2008.03.005 Di Monte, 2002, Environmental factors in Parkinson's disease, Neurotoxicology, 23, 487, 10.1016/S0161-813X(02)00099-2 Dohm, 2008, Aggregopathy in neurodegenerative disease: mechanisms and therapeutic implication, Neurodegenerative Dis., 5, 321, 10.1159/000119459 Fitzmaurice, 2006, Levels of 4-hydroxynonenal and malondialdehyde are increased in brain of human chronic users of methamphetamine, J. Pharmacol. Exp. Ther., 319, 703, 10.1124/jpet.106.109173 Fornai, 1995, Norepinephrine loss exacerbates methamphetamine-induced striatal dopamine depletion in mice, Eur. J. Pharmacol., 283, 99, 10.1016/0014-2999(95)00313-A Fornai, 2004, Similarities between methamphetamine toxicity and proteasome inhibition, Ann. N.Y. Acad. Sci., 1025, 162, 10.1196/annals.1316.021 Fornai, 2004, Methamphetamine produces neuronal inclusions in the nigrostriatal system and PC12 cells, J. Neurochem., 88, 114, 10.1046/j.1471-4159.2003.02137.x Gadient, 1997, Interleukin-6 (IL-6) a molecule with both beneficial and destructive potentials, Prog. Neurobiol., 52, 379, 10.1016/S0301-0082(97)00021-X Giovanni, 1995, Estimating hydroxyl radical content in rat brain using systemic and intraventricular salicylate: impact of methamphetamine, J. Neurochem., 64, 1819, 10.1046/j.1471-4159.1995.64041819.x Guilarte, 2001, Is methamphetamine abuse a risk factor in Parkinsonism?, Neurotoxicology, 22, 725, 10.1016/S0161-813X(01)00046-8 Harvey, 2000, Regional heterogeneity of dopaminergic deficits in vervet monkey striatum and substantia nigra after methamphetamine exposure, Exp. Brain Res., 133, 349, 10.1007/s002210000386 Hirota, 1996, Accelerated nerve regeneration in mice by upregulated expression of interleukin (IL) 6 and IL-6 receptor after trauma, J. Exp. Med., 183, 2627, 10.1084/jem.183.6.2627 Hodara, 2004, Functional consequences of α-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation, J. Biol. Chem., 279, 47746, 10.1074/jbc.M408906200 Hunter, 2007, Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system, J. Neurochem., 100, 1375, 10.1111/j.1471-4159.2006.04327.x Hunter, 2009, Intrastriatal lipopolysaccharide injection induces Parkinsonism in C57/B6 mice, J. Neurosci. Res., 87, 1913, 10.1002/jnr.22012 Jareno, 1998, Serum malondialdehyde in HIV seropositive children, Free Radic. Biol. Med., 24, 503, 10.1016/S0891-5849(97)00168-8 Jin, 2004, Quantitative proteomic analysis of mitochondrial proteins: relevance to Lewy body formation and Parkinson's disease, Mol. Brain Res., 134, 119, 10.1016/j.molbrainres.2004.10.003 Jin, 2007, Prostaglandin E2 receptor subtype 2 (EP2) regulates microglial activation and associated neurotoxicity induced by aggregated α-synuclein, J. Neuroimmunol., 4, 2 Kim, 1999, Protection of methamphetamine nigrostriatal toxicity by dietary selenium, Brain Res., 851, 76, 10.1016/S0006-8993(99)02122-8 Kim, 2000, Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia, J. Neurosci., 20, 6309, 10.1523/JNEUROSCI.20-16-06309.2000 Kim, 2000, Phenidone prevents kainite-induced neurotoxicity via antioxidant mechanisms, Brain Res., 874, 15, 10.1016/S0006-8993(00)02560-9 Kim, 2000, Selenium deficiency potentiates methamphetamine-induced nigral neuronal loss; comparison with MPTP model, Brain Res., 862, 247, 10.1016/S0006-8993(00)02085-0 Kim, 2003, New morphinan derivates with negligible psychotropic effects attenuate convulsions induced by maximal electroshock in mice, Life Sci., 72, 1883, 10.1016/S0024-3205(02)02505-5 Kita, 1998, Methamphetamine-induced neurotoxicity in BALB/c, DBA/2N and C57BL/6N mice, Neuropharmacology, 37, 1177, 10.1016/S0028-3908(98)00106-3 Kita, 2003, Current research on methamphetamine-induced neurotoxicity: animal models of monoamine disruption, J. Pharmacol., 92, 178 Koo, 2008, Methamphetamine potentiates lipopolysaccharide-induced dopaminergic toxicity in mice, P235 Korsmeyer, 1993, Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death, Semin. Cancer Biol., 4, 327 Koutsilieri, 2002, Free radicals in Parkinson's disease, J. Neurol., 249, II1, 10.1007/s00415-002-1201-7 LaVoie, 2004, Microglial activation precedes dopamine terminal pathology in methamphetamine-induced neurotoxicity, Exp. Neurol., 187, 47, 10.1016/j.expneurol.2004.01.010 Le Couteur, 1999, Pesticides and Parkinson's disease, Biomed. Pharmacother., 53, 122, 10.1016/S0753-3322(99)80077-8 Li, 2008, Phenidone protects the nigral dopaminergic neurons from LPS-induced neurotoxicity, Neurosci. Lett., 445, 1, 10.1016/j.neulet.2008.08.053 Lindner, 1996, Validation of a rodent model of Parkinson's disease: evidence of a therapeutic window for oral Sinemet, Brain Res. Bull., 39, 367, 10.1016/0361-9230(96)00027-5 Liu, 2003, Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention, J. Pharmacol. Exp. Ther., 304, 1, 10.1124/jpet.102.035048 Liu, 2000, Systemic infusion of naloxone reduces degeneration of rat substantia nigral dopaminergic neurons induced by intranigral injection of lipopolysaccharide, J. Pharmacol. Exp. Ther., 295, 125 Lorez, 1981, Fluorescence histochemistry indicates damage of striatal dopamine nerve terminals in rats after multiple doses of METH, Life Sci., 28, 911, 10.1016/0024-3205(81)90053-9 Manning-Bog, 2002, The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein, J. Biol. Chem., 277, 1641, 10.1074/jbc.C100560200 Marshall, 1997, Upregulation of the anti-apoptotic protein Bcl-2 may be an early event in neurodegeneration: studies on Parkinson's and incidental Lewy body disease, Biochem. Biophys. Res. Commun., 240, 84, 10.1006/bbrc.1997.7604 McGeer, 1988, Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains, Neurology, 38, 1285, 10.1212/WNL.38.8.1285 Meredith, 2002, Lysosomal malfunction accompanies alpha-synuclein aggregation in a progressive mouse model of Parkinson's disease, Brain Res., 956, 156, 10.1016/S0006-8993(02)03514-X Miller, 2009, Oxidative and inflammatory pathways in Parkinson's disease, Neurochem. Res., 34, 55, 10.1007/s11064-008-9656-2 Nicholas, 2008, Effects of levodopa on striatal monoamines in mice with levodopa-induced hyperactivity, Neurosci. Lett., 443, 204, 10.1016/j.neulet.2008.07.039 O’Callaghan, 1994, Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse, J. Pharmacol. Exp. Ther., 270, 741 Oliver, 1987, Age-related changes in oxidized proteins, J. Biol. Chem., 262, 5488, 10.1016/S0021-9258(18)45598-6 Paxinos, 2001 Reed, 1996, Mechanisms of Bcl-2 family protein function and dysfunction in health and disease, Behring Inst. Mitt., 97, 72 Reinheckel, 2000, Differential impairment of 20S and 26S proteasome activities in human hematopoietic K562 cells during oxidative stress, Arch. Biochem. Biophys., 377, 65, 10.1006/abbi.2000.1717 Sawada, 2004, Proteosome mediates dopaminergic neuronal degeneration, and its inhibition causes alpha-synuclein inclusions, J. Biol. Chem., 279, 10710, 10.1074/jbc.M308434200 Sekine, 2008, Methamphetamine causes microglial activation in the brains of human abusers, J. Neurosci., 28, 5756, 10.1523/JNEUROSCI.1179-08.2008 Sonsalla, 1996, Treatment of mice with methamphetamine produces cell loss in the substantia nigra, Brain Res., 738, 172, 10.1016/0006-8993(96)00995-X Spillantini, 1997, Alpha-synuclein in Lewy bodies, Nature, 388, 839, 10.1038/42166 Sriram, 2006, Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-α, J. Neurochem., 96, 706, 10.1111/j.1471-4159.2005.03566.x Steffensen, 1994, Site-specific hippocampal pathophysiology due to cerebral overexpression of interleukin-6 in transgenic mice, Brain Res., 652, 149, 10.1016/0006-8993(94)90329-8 Tetrud, 1989, MPTP-induced parkinsonism as a model for Parkinson's disease, Acta. Neurol. Scand. Suppl., 126, 35, 10.1111/j.1600-0404.1989.tb01780.x Thomas, 2004, Methamphetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglial activation, J. Pharmacol. Exp. Ther., 311, 1, 10.1124/jpet.104.070961 Thomas, 2004, Microglial activation is a pharmacologically specific marker for the neurotoxic amphetamines, Neurosci. Lett., 367, 349, 10.1016/j.neulet.2004.06.065 Thomas, 2005, MK-801 and dextromethorphan block microglial activation and protect against methamphetamine-induced neurotoxicity, Brain Res., 1050, 190, 10.1016/j.brainres.2005.05.049 United Nations Office on Drugs and Crime, 2009. World Drug Report 2009. United Nations Publication, New York. Wakabayashi, 1997, NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease, Neurosci. Lett., 239, 45, 10.1016/S0304-3940(97)00891-4 Walsh, 1992, Motor impairments after methamphetamine-induced neurotoxicity in the rat, J. Pharmacol. Exp. Ther., 263, 617 Webb, 2003, Alpha-Synuclein is degraded by both autophagy and the proteasome, J. Biol. Chem., 278, 25009, 10.1074/jbc.M300227200 Whitton, 2007, Inflammation as a causative factor in the aetiology of Parkinson's disease, Br. J. Pharmacol., 150, 963, 10.1038/sj.bjp.0707167 Wilson, 1996, Striatal dopamine nerve terminal markers in human, chronic methamphetamine users, Nat. Med., 2, 699, 10.1038/nm0696-699 Winson, 1996, Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease, Neurology, 47, 718, 10.1212/WNL.47.3.718 Zhang, 2006, 3-Hydroxymorphinan, a metabolite of dextromethorphan, protects nigrostriatal pathway against MPTP-elicited damage both in vivo and in vitro, FASEB J., 20, 2496, 10.1096/fj.06-6006com Zhong, 1995, Striatal dihydroxy-phenylalanine decarbxylase and tyrosine hydroxylase protein in idiopathic Parkinson's disease and dominantly inherited olivopontocerebellar atrophy, Mov. Disord., 101, 10, 10.1002/mds.870100104